TC
MRNS

Tejara Capital’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Tejara Capital’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-38,649
Closed -$267K – 94
2023
Q1 		$267K Sell
38,649
-57,179
-60% -$359K 0.14% 71
2022
Q4 		$381K Buy
+95,828
New +$471K 0.22% 70

Other funds holding MRNS

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

Tejara Capital's MRNS Position: Q2 2023 in Review

Tejara Capital sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q2 2023, closing a stake of 38,649 shares — an estimated $267K sold.

Tejara Capital first reported a position in MRNS in Q4 2022 and held it in 2 quarters. The position peaked at $381K in Q4 2022. 106 funds tracked by Wall St. Rank hold MRNS as of Q2 2023.

  • Tejara Capital reported no remaining Marinus Pharmaceuticals, Inc position as of Q2 2023 after selling out during the quarter.
  • Tejara Capital sold 38,649 Marinus Pharmaceuticals, Inc shares in Q2 2023, an estimated $267K.
  • Tejara Capital first reported a position in Marinus Pharmaceuticals, Inc in Q4 2022 and held it in 2 quarters.
  • Tejara Capital's Marinus Pharmaceuticals, Inc position peaked at $381K in Q4 2022.
  • 106 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q2 2023.

Based on Tejara Capital's 13F filing for Q2 2023, filed 11 Aug 2023.